Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 15/20 | 0.60 |
| ▸ | KIT | P10721 | 4/20 | 0.50 |
| ▸ | FLT3 | P36888 | 3/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | BCR | P11274 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2416867 | 0.91 | AURKA (0.61) | AURKAKITFLT3ABL1BCR | |
| SCHEMBL2419087 | 0.91 | AURKA (0.60) | AURKAKITFLT3 | |
| SCHEMBL2414063 | 0.91 | AURKA (0.60) | AURKAKITFLT3 | |
| SCHEMBL2419890 | 0.89 | AURKA (0.59) | AURKAKITFLT3 | |
| SCHEMBL2418296 | 0.89 | AURKA (0.76) | AURKAKITFLT3 | |
| SCHEMBL3882182 | 0.87 | AURKA (0.79) | AURKA | |
| SCHEMBL2416303 | 0.87 | AURKA (0.64) | AURKAKITFLT3 | |
| SCHEMBL2415038 | 0.87 | AURKA (0.64) | AURKAKITFLT3 | |
| SCHEMBL2417414 | 0.85 | AURKA (0.65) | AURKAKITFLT3ABL1BCR | |
| SCHEMBL2412343 | 0.84 | AURKA (0.65) | AURKAKITFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1530573-B1 | CONDENSED HETEROCYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PFIZER ITALIA SRL (IT) | 2008-03-19 | — | — | EP | claimed |
| US-8017643-B2 | Condensed heterocyclic pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-09-13 | — | — | US | disclosed |
| US-20100286223-A1 | Condensed Heterocyclic Pyrazole Derivatives as Kinase Inhibitors | PFIZER ITALIA S.R.L. (IT) | 2010-11-11 | — | — | US | disclosed |
| US-7786048-B2 | Condensed heterocyclic pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2010-08-31 | — | — | US | disclosed |
| US-20090233813-A1 | Condensed Heterocyclic Pyrazole Derivatives as Kinase Inhibitors | PFIZER ITALIA S.R.L. (IT) | 2009-09-17 | — | — | US | disclosed |
| US-7541378-B2 | Condensed heterocyclic pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2009-06-02 | — | — | US | disclosed |
| US-20060122249-A1 | Condensed heterocyclic pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2006-06-08 | — | — | US | disclosed |
| EP-1530573-A1 | CONDENSED HETEROCYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2005-05-18 | — | — | EP | disclosed |
| WO-2004013146-A1 | CONDENSED HETEROCYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A (IT) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286223-A1 | Condensed Heterocyclic Pyrazole Derivatives as Kinase Inhibitors | CDK2, MAP3K19, MAP3K15 | AURKA 41/4885KIT 432/4885FLT3 236/4885 |
| US-20060122249-A1 | Condensed heterocyclic pyrazole derivatives as kinase inhibitors | CDK2, MAP3K19, MAP3K15 | AURKA 41/4885KIT 432/4885FLT3 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.